Evidence map›Paper›PMID 24952158›Full record

ArticleBiochemical and biophysical research communications2014

Role of hydrophobic mutations on the binding affinity and stability of blood coagulation factor VIIIa: a computational molecular dynamics and free-energy analysis.

Divi Venkateswarlu

Open access · greenAbstract read
In one paragraph

Article in Biochemical and biophysical research communications, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Divi VenkateswarluDepartment of Chemistry, North Carolina Agricultural and Technical State University, Greensboro, NC 27411, USA. Electronic address: divi@ncat.edu.
North Carolina Agricultural and Technical State University · US

Funding

Investigation of protein interactions in intrinsic blood coagulation pathwayR15HL082632 · NHLBI · NORTH CAROLINA AGRI & TECH ST UNIV · PI VENKATESWARLU, DIVI · 2007 to 2007
$210k
NHLBI NIH HHS R15 HL082632NHLBI NIH HHS R15-HL082632
6 · The paper itself

Abstract

Factor VIIIa is a non-covalently bound hetero-trimer among A1, A2 and A3-C1-C2 domains and an essential co-factor for factor IXa enzyme during proteolytic activation of factor X zymogen. The relatively weak interactions between A2 and the interface A1/A3 domains dampen the functional stability of FVIIIa in plasma and results in rapid degradation. We studied the mutational effect of three charged residues (Asp519, Glu665 and Asp666) to several hydrophobic residues by molecular dynamics simulations. Analysis of the binding free energy by MM-PBSA and MM-GBSA methods shows that the mutation of Asp519 and Glu665 residues to either Val or Ala enhance the A2 domain binding affinity in agreement with the experimental site-specific mutagenesis data. Mutation of Asp666 to Val, Tyr, Met and Phe showed largest improvement in the A2-domain binding among the eight hydrophobic mutants studied. Our studies suggest that the enrichment of hydrophobic interactions in the buried surface regions of A2 domain plays crucial role in improving the overall stability of FVIIIa.

Indexed as

Models, ChemicalMolecular Dynamics SimulationBinding SitesComputer SimulationDrug StabilityEnergy TransferFactor VIIIaHydrophobic and Hydrophilic InteractionsMutagenesis, Site-DirectedProtein BindingProtein ConformationStructure-Activity RelationshipThermodynamicsFactor VIIIaBinding free-energyFactor VIIIaHemophilia-AMM-PBSAMolecular dynamics

Identifiers

PMID24952158
PMCPMC4123457
OpenAlexW1998055270

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.